16:34, 27 июня 2026, Bishkek - 24.kg news agency , Anastasia BENGARD
Manufacturers of pharmaceuticals and medical products in Kyrgyzstan will gain access to preferential lending under a newly approved state support program, the Ministry of Economy and Commerce of Kyrgyzstan reported.
According to the ministry, the project is aimed at supporting the domestic pharmaceutical industry, modernizing production facilities, introducing international quality standards, and strengthening the country’s medicines security.
Currently, the pharmaceutical industry accounts for only about 0.1 percent of Kyrgyzstan’s total industrial output.
Around 30 pharmaceutical manufacturers and 16 medical device producers are currently operating in the republic.
At the same time, approximately 96 percent of domestic demand for medicines and medical products is covered by imports.
Under the requirements of the Eurasian Economic Union, domestic manufacturers must bring their production facilities into compliance with EAEU Good Manufacturing Practice (GMP) requirements and the international ISO 13485 standard by the end of 2027. This will require significant investment in upgrading production, constructing and renovating facilities, purchasing modern equipment, establishing quality control laboratories, and implementing product traceability systems.
To address these challenges, the government is introducing a preferential lending mechanism for pharmaceutical and medical device manufacturers.
Under the program, companies will be eligible for concessional financing in the following areas:
Preferential loans will be provided at annual interest rates of 3 percent and 5 percent, with repayment periods of up to 10 and 12 years respectively, including a grace period of up to 24 months for principal repayment.
The total financing volume of the project exceeds 3.16 billion soms.
This includes 500 million soms allocated to increase the charter capital of State Development Bank of the Kyrgyz Republic. These funds will be used to implement the preferential lending mechanism.
The project is expected to boost domestic production of medicines and medical devices, reduce dependence on imports, create new jobs, improve the competitiveness of national manufacturers, and strengthen the country’s pharmaceutical security.
In addition, compliance with EAEU GMP requirements and ISO 13485 standards is expected to expand export opportunities for Kyrgyz producers and facilitate access to markets across EAEU member states and other countries.